AGOURON announces EXPANDED ACCESS Program 9/17/96

Agouron announced an expanded access for their protease inhibitor nelfinavir.

If you are interested in participating, the expanded access telephone number is : 1-800-621-7111.

In order to register your doctor must contact the program to officially register a patient. Initial registration includes requiring:

• documented CD4 count below 50 cells within last 90 days
• unable to use 3 approved protease inhibitors--saquinavir, ritonavir, indinavir--due to intolerance, contraindication, or prior failure.

Access to nelfinavir in this program is first-come-first served. You MUST call quickly and register. There is no lottery. If more aplications come in than available spots, you will be put on a waiting list.

Agouron's web-site also has information on the expanded access program : http://www.agouron.com.

Related articles:

• nelfinavir pediatrics study (9/14/96)
• nelfinavir: preliminary efficacy & safety data update (9/3/96)
• nelfinavir resistance profile (8/15/96)